Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
S. Khadka, Y.-H. Lin, J. J. Ackroyd, Y.-A. Chen, Y. Sheng, W. Qian, S. Guo, Y. Chen, E. I. Behr, Y. Barekatain, M. N. Uddin, K. Arthur, V. C. Yan, E. Chang, A. Poral, , F. L. Muller
This study shows that angiogenesis inhibitors enhance the effectiveness of metabolic therapies in gliomas by inducing anaplerotic nutrient stress.
bioRxiv · May 7, 2023 · PreprintCancer Biology
D. Awad, T. L. Pulliam, M. L. Spradlin, P. H.-A. Cao, E. Subramani, T. V. Tellman, C. F. Ribeiro, H. Pakula, J. J. Ackroyd, M. M. Murray, J. J. Han, B. Piyarathna, J. M. Drake, M. M. Ittmann, C. Coarfa, , D. E. Frigo
This study identifies ATGL as a CAMKK2-AMPK target that promotes CRPC progression by enhancing lipase activity and metabolic plasticity, suggesting it as a therapeutic target.
bioRxiv · Nov 2, 2022 · PreprintCancer Biology
T. L. Pulliam, D. Awad, J. J. Han, M. M. Murray, J. J. Ackroyd, P. Goli, J. S. Oakhill, J. W. Scott, M. M. Ittmann, D. E. Frigo
This study shows that deleting Camkk2 in TRAMP mice reduces metastasis and improves insulin sensitivity, suggesting CAMKK2 has non-autonomous roles in prostate cancer progression.
bioRxiv · Mar 28, 2022Cancer Biology
V. C. Yan, C.-D. Pham, M. J. Yan, A. J. Yan, S. Khadka, K. Arthur, J. J. Ackroyd, D. K. Georgiou, L. E. Roon, L. R. Bushman, P. L. Anderson, C. Li, F. L. Muller
This study evaluates the oral bioavailability of GS-441524 in dogs, showing sustained plasma concentrations above the EC50 for SARS-CoV-2.
bioRxiv · Feb 4, 2021 · PreprintPharmacology & Toxicology
Y. Barekatain, V. C. Yan, K. Arthur, J. J. Ackroyd, S. Khadka, J. De Groot, J. T. Huse, F. L. Muller
This paper demonstrates that 1H-13C HSQC NMR can detect oncometabolic aberrations in live cells and tumors without specialized equipment, improving sensitivity and resolution over traditional methods.
bioRxiv · Dec 18, 2019Biophysics
Y. Barekatain, V. C. Yan, J. J. Ackroyd, A. H. Poral, T. Tran, D. K. Georgiou, K. Arthur, A. deCarvalho, Y.-H. Lin, N. B. Satani, E. S. Ballato, R. Verhaak, J. de Groot, J. T. Huse, J. M. Asara, F. L. Muller
This paper shows that MTA levels are not significantly elevated in MTAP-homozygous deleted primary human glioblastomas, challenging the clinical relevance of targeting PRMT5 and MAT2A in these tumors.
bioRxiv · Oct 18, 2019Cancer Biology